InvestorsHub Logo
Followers 826
Posts 119569
Boards Moderated 14
Alias Born 09/05/2002

Re: DewDiligence post# 796

Friday, 10/12/2018 8:59:31 AM

Friday, October 12, 2018 8:59:31 AM

Post# of 1162
Opdivo fails in second-line SCLC—CHECKMATE-331 tested Opdivo monotherapy vs standard chemo with OS primary endpoint:

https://finance.yahoo.com/news/bristol-myers-squibb-announces-phase-105900779.html

No OS hazard ratio or further details at this time.

Note: Opdivo monotherapy was recently FDA-approved in third-line SCLC based on single-arm ORR data (#msg-142984905).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News